Genetic Analysis AS (FRA:8V8)

Market Cap	3.36M -36.7%
Revenue (ttm)	1.80M -8.1%
Net Income	-1.14M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,200
Open	0.0304
Previous Close	0.0342
Day's Range	0.0304 - 0.0304
52-Week Range	0.0020 - 0.0805
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 20, 2026

About Genetic Analysis AS

Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome research assay; GA-map Sample Collection Kit for the collection, transport, a...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 18
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8V8

Financial Performance

In 2025, Genetic Analysis AS's revenue was 21.17 million, an increase of 2.36% compared to the previous year's 20.68 million. Losses were -11.41 million, -22.72% less than in 2024.

Financial numbers in NOK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error